insights_auto
4142 පහත වැටී ඇත්තේ ඇයි 6.62%?
වඩාත් ගැඹුරට කිමිදෙන්නchevron_right
4142:TPE
Adimmune Corp
NT$14.80
arrow_downward
-6.62%(-1.05) 1D
ඉල් 20, 13:30:09 ග්රිමවේ+8 · TWD
search
සියලු සංකේත
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_auto4142 සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
NT$15.75
ඉහළ
NT$15.75
පහළ
NT$14.80
වෙ.පො ප්රාග්ධනය
බි6.36
දළ පරිමාව
මි1.13
හඬ පරිමාණය
මි1.63
P/E අනුපාතය
85.76
සති-52 ඉහළ
NT$21.50
සති-52 පහළ
NT$14.80
EPS
NT$0.17
ගෙවිය යුතු කොටස්
මි235.29
සේවකයින් ගණන
564
විවෘත කරන්න
NT$15.75
ඉහළ
NT$15.75
පහළ
NT$14.80
වෙ.පො ප්රාග්ධනය
බි6.36
දළ පරිමාව
මි1.13
හඬ පරිමාණය
මි1.63
P/E අනුපාතය
85.76
සති-52 ඉහළ
NT$21.50
සති-52 පහළ
NT$14.80
EPS
NT$0.17
ගෙවිය යුතු කොටස්
මි235.29
සේවකයින් ගණන
564
පුවත් සහ කථා
වෙබ් මූලාශ්ර සහ ප්රවෘත්ති හවුල්කරුවන්ගෙන්
Yahoo Finance
·
පැය 2කට පෙර
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
Beinsure
·
පැය 7කට පෙර
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
Benzinga
·
පැය 4කට පෙර
S&P 500 Has Slumped Into a Correction as Goldman Sachs Panic Index Points to More Downside
24/7 Wall St.
·
පැය 6කට පෙර
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
පැතිකඩ
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp ගැන